Tag: Press Release

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ER-100. The IND clearance allows Life Bio to initiate a clinical program evaluating ER-100’s safety and...

Roatán, Honduras — Rejuve.AI is activating the International Longevity Research Database (IRLDB) through its first real-world study cohort at the Longevity Biomarkers Competition and Summit, taking place February to March 2026 as part of the Infinite Games in Roatán, Honduras. The IRLDB is being activated through its first registered, consented cohort. Participants enrolled in the...

The Longevity World Forum announces its move to Madrid, reinforcing its international positioning with a new location aligned with its growth and leadership objectives in the field of longevity science and healthy ageing. The Spanish capital beats the cities that were postulated as possible venues for the next edition and thus adds an important asset...

Longevity Investors announces the upcoming Longevity Investors Lunch 2026, an exclusive, application-only gathering designed specifically for investors seeking exposure to the most compelling opportunities emerging at the intersection of longevity science, technology, and capital. Held during the World Economic Forum in Davos, the event convenes a highly curated group of global investors alongside select longevity...

Why do we age at all, and why do different species age at such dramatically different rates? After decades of longevity research, biologists still disagree on the most basic questions: What is aging? Is it possible to stop or reverse it? And what strategies stand a real chance of working? Most gerontologists explain aging as...

Cambridge, MA, USA – November 18, 2025: Vincere Biosciences today announced the receipt of a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutics Pipeline Program, which supports the advancement of promising therapies through preclinical and clinical stages. The initiative focuses on candidates with strong potential to slow...